Skip to main content
Premium Trial:

Request an Annual Quote

Waters, Dotmatics, Sigma-Aldrich, Phenomenex, Beckman Coulter, Eksigent, Bionoetikos, Digilab, GenWay, DeltaDot, INCAPS, Agilent, Stratagene

Waters, Dotmatics Co-develop Tools for Waters MS
Waters and Dotmatics said this week they will develop an integrated advanced structure elucidation tool to complement Waters’ TOF mass spectrometers and Synapt and MALDI Synapt HDMS systems.
The two companies will develop tools based on Dotmatics’ and Waters’ MassLynx MetaboLynx Application Manager software for structural elucidation of small molecules.
Terms of the agreement were not disclosed.

Sigma-Aldrich Invites Researchers to its AQUA Program
Sigma-Aldrich said this week that proteomic researchers ordering its custom absolute quantitation peptides will be invited to join its newly formed AQUA Peptide Partnership Program.
In addition, AQUA peptide sequences will be added to Sigma-Aldrich's growing AQUA Peptide Library, and contributors will receive partnership pricing on their custom orders, the company said.
The AQUA Peptide Library, initially developed in collaboration with the Protein Quantitation Consortium, will contain hundreds of AQUA Peptides, Sigma said.
Sigma-Aldrich said the AQUA initiative “enables focused, quantitative mass spectrometric studies” of protein biomarkers and amino acids.
The company said the technique also allows researchers to use mass spectrometry to validate gene silencing at the protein level.

Phenomenex Distributes Beckman Coulter Columns
Phenomenex this week said it has reached a distribution agreement for Beckman Coulter’s ProteomeLab IgY enrichment products for proteomics and biomarker discovery.
Under the terms of the agreement Phenomenex has exclusive distribution rights in the US, Canada, and the European Union.
In a statement, Jerry Feitelson, business development manager for Beckman said the ProteomeLab IgY product line has grown at a double-digit rate since 2005 and the company had been looking to expand its availability.
Financial terms of the deal were not disclosed.

Eksigent, Bionoetikos Ink Distribution Deal in Asia
Eksigent announced this week it has reached an agreement with Hong Kong’s Bionoetikos for the distribution of Eksigent’s NanoLC HPLC product line in parts of Asia.
The agreement covers Taiwan, Indonesia, the Philippines, Vietnam, Malaysia, Singapore, Cambodia, Thailand, and Laos. No financial details of the deal were released.
Bionoetikos is a life science consulting and distribution firm focusing on Asia.

Digilab, GenWay Ink Distribution Deal
Digilab BioVisionN will become the European distributor of products based on GenWay Biotech’s Seppro technology, the companies announced this week.
Terms of the agreement were not disclosed.
Seppro IgY selectively partitions the 12 most abundant proteins in human serum and plasma, the companies said in a statement.

DeltaDot, Others, Receive $927K to Develop Drug Development Tool
DeltaDot and Integrated Technologies said this week they have received a £465,000 ($927,000) grant from the South East England Development Agency to develop a new tool that will use protein-folding structures to help speed drug development.
The system, called the Osprey Biomolecule Stability Analyzer, is a microfluidic instrument that uses DeltaDot's Label Free Intrinsic Imaging to characterize protein properties. The system is being developed to test drug candidates against protein structures and dynamics, the company said.
The company is targeting the market for biopharmaceutical quality assurance as the first application for Osprey. 

Now Monarch, Once INCAPS
The Indiana Centers for Applied Protein Sciences, INCAPS, this week said they have changed their name to Monarch LifeSciences.
Monarch is a contract research organization specializing in protein biomarker discovery, development, and validation. It was formed through Indiana’s BioCrossroads, an initiative to grow the states life science business, companies such as Eli Lilly, and academic institutions including Indiana University, the IU School of Medicine, and Purdue University.

Agilent Expects 2- to 5-Percent Decline in Q3 Revenue; Closes Stratagene Buy
Agilent Technologies this week said it expects third-quarter revenue to decline between 2 percent and 4.8 percent year over year, or to between $1.38 billion and $1.42 billion from $1.45 billion last year.
The company also said it has closed its acquisition of Stratagene for $10.94 a share, or $246 million.
Agilent said Stratagene has more than 450 employees, who have now joined the firm. The company did not mention trimming Stratagene’s workforce.
Stratagene has operations in Texas, California, Japan, and Amsterdam.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.